Home › Burkitt Lymphoma › District of Columbia › Washington
Burkitt Lymphoma clinical trials in Washington, DC
9 studies for Burkitt Lymphoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi away
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecruitingPhase 2
- MedStar Georgetown University Hospital, Washington D.C.
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Children's National Medical Center, Washington D.C.
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi away
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Children's National Medical Center, Washington D.C.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Children's National Medical Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi away
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Philadelphia, PA16 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- New York City, NY13 studies
- Cincinnati, OH13 studies
- Atlanta, GA12 studies
- Aurora, CO11 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Kansas City, MO10 studies
- Boston, MA10 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.